Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 30;9(11):1966-1972.
doi: 10.7150/jca.24550. eCollection 2018.

Involvement of non-coding RNAs in chemotherapy resistance of ovarian cancer

Yang Shao  1   2 , Hui Li  2   3 , Ran Du  2   3 , Jiao Meng  1   2 , Gong Yang  1   2   3
Affiliations
Review

Involvement of non-coding RNAs in chemotherapy resistance of ovarian cancer

Yang Shao et al. J Cancer. .

Abstract

Ovarian cancer (OC) is the most lethal gynecological malignancy, with a low 5-year survival rate. Most patients with ovarian cancer are diagnosed in late-stages. A rising number of non-coding RNAs (ncRNAs) have been found to act as key regulators of gene expression by applying novel high-thought methods, such as next generation sequencing (NGS). Non-coding RNAs not only play important roles in carcinogenesis, but also affect the clinical treatment strategies. One of the biggest challenge in OC treatment was chemoresistance, which causes poor prognosis and high recurrence rate after applying traditional remedies. Of note, it has been proved that ncRNAs were deeply correlated with chemoresistance in several cancers, which made ncRNAs considered to be potential therapeutic targets in ovarian cancer. Among of all ncRNAs, the studies of miRNAs and lncRNAs in ovarian cancer chemoresistance were much clearer. In this study, we reviewed the most relevant researches in this field, and described the relationships between ncRNAs and chemoresistance in ovarian cancer.

Keywords: chemoresistance; lncRNAs; miRNAs; ncRNAs; ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
The relationships between ncRNAs and chemotherapy resistance in ovarian cancer
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Cancer statistics in China, 2015. CA: a cancer journal for clinicians; 2016. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: a cancer journal for clinicians. 2017;67:7–30. - PubMed
    1. Di Leva G, Croce CM. miRNA profiling of cancer. Current opinion in genetics & development. 2013;23:3–11. - PMC - PubMed
    1. Prat J, Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2014;124:1–5. - PubMed
    1. van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ. et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer. 2001;92:2837–44. - PubMed